NuVasive, Inc. (NUVA)
(Delayed Data from NSDQ)
$62.96 USD
+0.74 (1.19%)
Updated May 3, 2019 04:00 PM ET
After-Market: $62.96 (%) 5:22 PM ET
NA Value
NA Growth NA Momentum NA VGMWe use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$62.96 USD
+0.74 (1.19%)
Updated May 3, 2019 04:00 PM ET
After-Market: $62.96 (%) 5:22 PM ET
NA Value
NA Growth NA Momentum NA VGM
Zacks News
Polaris, 58.com, BlackRock, Intuitive Surgical, Medtronic and NuVasive as Zacks Bull and Bear of the Day
by Zacks Equity Research
Polaris, 58.com, BlackRock, Intuitive Surgical, Medtronic and NuVasive as Zacks Bull and Bear of the Day
3 Stocks to Tap the Minimally-Invasive Surgery Market Boom
by Sweta Jaiswal
Consider these three stocks in the rapidly-growing minimally-invasive surgical device market.
NuVasive's (NUVA) Global Prospects Solid, Competition Rife
by Zacks Equity Research
NuVasive (NUVA) demonstrates strong sales growth across all geographies. Competitive landscape is a concern.
Why is NuVasive (NUVA) Down 5.7% Since its Last Earnings Report?
by Zacks Equity Research
NuVasive (NUVA) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
NuVasive (NUVA) Q1 Earnings Miss Estimates, Revenues In Line
by Zacks Equity Research
NuVasive (NUVA) gains on continued growth in international business along with strong case volume growth in the U.S. Hardware business in Q1.
Why Is NuVasive (NUVA) Up 4.6% Since Its Last Earnings Report?
by Zacks Equity Research
NuVasive (NUVA) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
NuVasive Gains From International Business Amid Pricing Woes
by Zacks Equity Research
Sturdy performance of NuVasive's (NUVA) international business with more than 20% growth for the fifth consecutive quarter raises optimism among investors
NuVasive (NUVA) Meets Q4 Earnings Estimates, Issues '18 View
by Zacks Equity Research
NuVasive (NUVA) gains on continued growth in international business in Q4.
Can Segmental Strength Drive Integra's (IART) Q4 Earnings?
by Zacks Equity Research
Integra LifeSciences (IART) well poised to gain from strength in Orthopedics and Tissue Technologies in Q4.
What's in the Cards for Genomic Health (GHDX) in Q4 Earnings?
by Zacks Equity Research
Similar to last quarter, Genomic Health (GHDX) is expected to gain from higher total product revenues in Q4.
International Business Aids NuVasive, Pricing Woe Remains
by Zacks Equity Research
NuVasive (NUVA) plans to merge its U.S. Commercial and International sales functions into a global commercial organization. Also, several recent FDA approvals are encouraging.
NuVasive's SpineTRACK Registry Gains New CMS Designation
by Zacks Equity Research
NuVasive's (NUVA) receipt of the QCDR designation for its SpineTRACK buoys optimism for the stock. This achievement might add value to cushion its efforts to provide systems-based spine solutions.
NuVasive Q4 Preliminary Results Fail to Cheer Investors
by Zacks Equity Research
NuVasive (NUVA) continues to witness sequential growth in international revenues and expects substantial tax savings from the recent U.S. tax reform.
NuVasive (NUVA) Global Prospects Solid, Pricing Woes Remain
by Zacks Equity Research
NuVasive (NUVA) witnesses solid top-line contributions from the international business.
NuVasive (NUVA) to Acquire SafePassage, Strengthens IONM
by Zacks Equity Research
NuVasive's (NUVA) combined entity with SafePassage seems strategic as the move will fortify the NuVasive Clinical Services' (NCS) status as the largest U.S. provider of outsourced IONM services.
NuVasive (NUVA) in Focus: Stock Moves 8.4% Higher
by Zacks Equity Research
NuVasive, Inc. (NUVA) saw its shares rise over 8% on the day after the company reported better-than-expected third-quarter results and announced a major stock repurchase program.
New Strong Sell Stocks for October 26th
by Zacks Equity Research
Here are 5 stocks added to the Zacks Rank #5 (Strong Sell) List today:
NuVasive (NUVA) Q3 Earnings Top, Revenues Lag, Guidance Cut
by Zacks Equity Research
NuVasive's robust top-line growth in Q3 was driven by strong international performance. However, U.S. sales declined on procedural volume challenges and an adverse impact of the recent natural disasters.
NuVasive's TLX Interbody System Gets Expanded FDA Approval
by Zacks Equity Research
NuVasive (NUVA) leaves no stone unturned to cash in on the rapidly-evolving spine market.
NuVasive's (NUVA) PRECICE System Gets Expanded FDA Approval
by Zacks Equity Research
NuVasive's (NUVA) latest receipt of expanded FDA 510(k) approval for PRECICE is likely to fortify its hold in the limb reconstruction and trauma market.
NuVasive Acquires Vetera Spine, Grows With Spinal Hardware
by Zacks Equity Research
NuVasive aims to market and distribute Vetera Spine's FDA-approved COHERE Cervical and COALESCETM Lumbar Interbody fusion devices in the United States.
NuVasive Launches Breakthrough in MIS Surgery -- LessRay
by Zacks Equity Research
NuVasive's latest LessRay system reduces radiation emission and exposure. The stock is likely to gain on number of vital developments despite a brief dull phase in between.
NuVasive Announces Vertera Spine Buyout, Boosts Implants Suite
by Zacks Equity Research
NuVasive (NUVA) to add three-dimensional porous interbody technology across polyetheretherketone (PEEK) material as well through the Vertera Spine buyout.
NuVasive Grows in Pediatric Deformity With New FDA Approval
by Zacks Equity Research
NuVasive (NUVA) has progressed with its 'Embracing the Journey Together' program with the FDA nod to use the company's redesigned MAGEC system with its RELINE Small Stature system.
NuVasive (NUVA) to Expand San Diego Global Headquarters
by Zacks Equity Research
Apart from introducing sophisticated features at the facility, NuVasive (NUVA) plans to open an innovation center of excellence at the San Diego global headquarters.